Reply to correspondence on “Comparative risk of fibrosis progression with sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitors in metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus with low-to-intermediate fibrosis”
Abstract
Reply to correspondence on "Comparative risk of fibrosis progression with sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitors in metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus with low-to-intermediate fibrosis"
Fields of Study & Subjects
Liver Disease Diagnosis and Treatment
Diabetes Treatment and Management
Chronic Kidney Disease and Diabetes
Publication details
- Journal / source
- Clinical and Molecular Hepatology
- Volume
- 32
- Issue
- 3
- Pages
- e434–e436
- Publication date
- 6 February 2026
- Language
- EN